Kronos Bio, Inc. (KRON)

Kronos Bio Statistics

Total Valuation

Kronos Bio has a market cap or net worth of $60.34 million. The enterprise value is -$38.72 million.

Market Cap	60.34M
Enterprise Value	-38.72M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025, before market open.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Kronos Bio has 60.34 million shares outstanding. The number of shares has increased by 3.92% in one year.

Current Share Class	60.34M
Shares Outstanding	60.34M
Shares Change (YoY)	+3.92%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	28.79%
Owned by Institutions (%)	30.77%
Float	42.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.04
Forward PS	n/a
PB Ratio	0.54
P/TBV Ratio	0.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.32, with a Debt / Equity ratio of 0.23.

Current Ratio	8.32
Quick Ratio	8.12
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-46.83

Financial Efficiency

Return on equity (ROE) is -59.08% and return on invested capital (ROIC) is -28.26%.

Return on Equity (ROE)	-59.08%
Return on Assets (ROA)	-25.13%
Return on Invested Capital (ROIC)	-28.26%
Return on Capital Employed (ROCE)	-57.94%
Revenue Per Employee	$156,571
Profits Per Employee	-$1.36M
Employee Count	63
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.66% in the last 52 weeks. The beta is 1.81, so Kronos Bio's price volatility has been higher than the market average.

Beta (5Y)	1.81
52-Week Price Change	-5.66%
50-Day Moving Average	0.99
200-Day Moving Average	1.01
Relative Strength Index (RSI)	50.71
Average Volume (20 Days)	225,954

Short Selling Information

The latest short interest is 937,506, so 1.55% of the outstanding shares have been sold short.

Short Interest	937,506
Short Previous Month	574,804
Short % of Shares Out	1.55%
Short % of Float	2.19%
Short Ratio (days to cover)	4.20

Income Statement

In the last 12 months, Kronos Bio had revenue of $9.86 million and -$85.59 million in losses. Loss per share was -$1.44.

Revenue	9.86M
Gross Profit	9.86M
Operating Income	-78.02M
Pretax Income	-102.85M
Net Income	-85.59M
EBITDA	-76.23M
EBIT	-78.02M
Loss Per Share	-$1.44

Balance Sheet

The company has $124.86 million in cash and $25.80 million in debt, giving a net cash position of $99.06 million or $1.64 per share.

Cash & Cash Equivalents	124.86M
Total Debt	25.80M
Net Cash	99.06M
Net Cash Per Share	$1.64
Equity (Book Value)	111.13M
Book Value Per Share	1.84
Working Capital	112.54M

Cash Flow

In the last 12 months, operating cash flow was -$77.62 million and capital expenditures -$31,000, giving a free cash flow of -$77.66 million.

Operating Cash Flow	-77.62M
Capital Expenditures	-31,000
Free Cash Flow	-77.66M
FCF Per Share	-$1.29

Margins

Gross Margin	100.00%
Operating Margin	-790.92%
Pretax Margin	-867.66%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kronos Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.92%
Shareholder Yield	-3.92%
Earnings Yield	-141.84%
FCF Yield	-128.69%

Analyst Forecast

The average price target for Kronos Bio is $1.63, which is 63.00% higher than the current price. The consensus rating is "Buy".

Price Target	$1.63
Price Target Difference	63.00%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	49.92%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kronos Bio has an Altman Z-Score of -5.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.06
Piotroski F-Score	3